製品の概要

  • 製品名Anti-HRPT2 antibody
    HRPT2 一次抗体 製品一覧
  • 製品の詳細
    Mouse polyclonal to HRPT2
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat, Chicken, Dog, Xenopus laevis, Cynomolgus Monkey
  • 免疫原

    Vector coding for a partial recombinant fusion protein, corresponding to internal sequence amino acids 331-430 of Human HRPT2. Target sequence used to make the antibody: KTQTPAAQPV PRPVSQARPP PNQKKGSRTP IIIIPAATTS LITMLNAKDL LQDLKFVPSD EKKKQGCQRE NETLIQRRKD QMQPGGTAIS VTVPYRVVDQ.

  • 特記事項


    This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
  • バッファーPreservative: None
    Constituents: 50% Glycerol, Whole serum
  • 精製度Whole antiserum
  • 一次抗体 備考This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.
  • ポリ/モノポリクローナル
  • アイソタイプIgG
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab43256 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB 1/1000. Predicted molecular weight: 61 kDa.

This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.

ターゲット情報

  • 機能Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of MLL1; it promotes leukemogenesis though association with MLL-rearranged oncoproteins, such as MLL-MLLT3/AF9 and MLL-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors.
  • 組織特異性Found in adrenal and parathyroid glands, kidney and heart.
  • 関連疾患Defects in CDC73 are a cause of familial isolated hyperparathyroidism (FIHP) [MIM:145000]; also known as hyperparathyroidism type 1 (HRPT1). FIHP is an autosomal dominant disorder characterized by hypercalcemia, elevated parathyroid hormone (PTH) levels, and uniglandular or multiglandular parathyroid tumors.
    Defects in CDC73 are the cause of hyperparathyroidism-jaw tumor syndrome (HPT-JT) [MIM:145001]; also known as hyperparathyroidism type 2 (HRPT2) or familial primary hyperparathyroidism with multiple ossifying jaw fibromas. HPT-JT is an autosomal dominant, multiple neoplasia syndrome primarily characterized by hyperparathyroidism due to parathyroid tumors. Thirty percent of individuals with HPT-JT may also develop ossifying fibromas, primarily of the mandible and maxilla, which are distinc from the brown tumors associated with severe hyperparathyroidism. Kidney lesions may also occur in HPT-JT as bilateral cysts, renal hamartomas or Wilms tumors.
    Defects in CDC73 are a cause of parathyroid carcinoma (PRTC) [MIM:608266]. These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.
  • 配列類似性Belongs to the CDC73 family.
  • 細胞内局在Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • C1orf28 antibody
    • CDC 73 antibody
    • Cdc73 antibody
    • CDC73_HUMAN antibody
    • Cell division cycle 73 antibody
    • Cell division cycle 73 Paf1/RNA polymerase II complex component homolog antibody
    • Cell division cycle protein 73 homolog antibody
    • FLJ23316 antibody
    • HPT JT antibody
    • HPTJT antibody
    • HRPT 2 antibody
    • Hyperparathyroidism 2 (with jaw tumor) antibody
    • Hyperparathyroidism 2 antibody
    • Hyperparathyroidism 2 protein antibody
    • HYX antibody
    • Parafibromin antibody
    see all

Anti-HRPT2 antibody 画像

  • All lanes : Anti-HRPT2 antibody (ab43256) at 1/1000 dilution

    Lane 1 : a total protein extract from E coli with 50ng to 100ng of a tagged fusion protein of an irrelevant antigen
    Lane 2 : a total protein extract from E coli with 50ng to 500ng of the antigen (Tagged fusion protein)

    Lysates/proteins at 20 µg per lane.

    Secondary
    Lane 1 : Rabbit anti-mouse IgG + IgM (H+L), HRP conjugated, at 1/5000 dilution
    Lane 2 : Rabbit anti-mouse IgG + IgM (H+L), HRP conjugated at 1/5000 dilution


    Predicted band size : 61 kDa

Anti-HRPT2 antibody (ab43256) 使用論文

ab43256 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab43256.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"